Absci Corporation (ABSI)
| Market Cap | 1.52B +161.3% |
| Revenue (ttm) | 1.56M -62.3% |
| Net Income | -121.08M |
| EPS | -0.80 |
| Shares Out | 171.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,395,649 |
| Open | 8.43 |
| Previous Close | 8.74 |
| Day's Range | 8.23 - 8.95 |
| 52-Week Range | 2.24 - 12.06 |
| Beta | 2.28 |
| Analysts | Strong Buy |
| Price Target | 14.50 (+63.29%) |
| Earnings Date | Nov 12, 2026 |
About ABSI
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Ket... [Read more]
Financial Performance
In 2025, Absci's revenue was $2.80 million, a decrease of -38.24% compared to the previous year's $4.53 million. Losses were -$115.18 million, 11.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price target is $14.5, which is an increase of 63.29% from the latest price.
News
Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026
VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generati...
Absci price target raised to $15 from $14 at JPMorgan
JPMorgan raised the firm’s price target on Absci (ABSI) to $15 from $14 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first on…
Absci announces preliminary details for Phase 2 Storyline trial of ABS-201
Absci (ABSI) announced additional details for the company’s planned global, multi-center Phase 2 Storyline clinical trial evaluating ABS-201, an investigational anti-prolactin receptor antibody engine...
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial i...
Absci Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
AI-driven R&D and China partnerships are accelerating clinical progress, with ABS-201 for pattern hair loss showing strong safety, promising durability, and significant market potential. Endometriosis trials begin this quarter, and a robust cash position supports operations through major data readouts.
Absci Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company has shifted to a clinical-stage focus, advancing AI-driven programs for pattern hair loss and endometriosis, with key data readouts expected in late 2024 and early 2025. Its proprietary Atlas and Origin platforms accelerate discovery, and a strong cash position supports operations through 2028.
Absci initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Absci (ABSI) with an Outperform rating and $16 price target
Absci price target raised to $15 from $13 at BTIG
BTIG analyst Kambiz Yazdi raised the firm’s price target on Absci (ABSI) to $15 from $13 and keeps a Buy rating on the shares. ABS-201 offers a differentiated, non-hormonal approach…
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Sept.
Absci reports Q2 EPS (21c), consensus (20c)
Reports Q2 revenue $318,000, consensus $931,670. “The positive Phase 1 interim data from our HEADLINE trial, combined with our strengthened balance sheet and advancing platform, position us well for w...
Absci Earnings Call Transcript: Q2 2026
Positive interim Phase I data for ABS-201 supports a convenient dosing schedule and strong safety profile. Strategic partnership and investment from Eli Lilly, along with a $100 million financing, extend cash runway into 2028 and enable continued pipeline expansion.
Absci Earnings release: Q2 2026
Absci released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Absci Quarterly report: Q2 2026
Absci has published its Q2 2026 quarterly earnings report on August 11, 2026.
Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash...
Absci Slides: Corporate presentation
Absci has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Absci management to meet virtually with KeyBanc
Virtual Meeting to be held on July 31 hosted by KeyBanc.
Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generati...
Absci director buys $149K in common stock
In a regulatory filing, Absci (ABSI) disclosed that its director Mary Szela bought 12.9K shares of common stock on July 1 in a total transaction size of about $149K. Shares…
Healthcare stocks have become a haven for investors ditching tech
Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.
Absci price target raised to $10 from $4.10 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Absci (ABSI) to $10 from $4.10 and keeps an Equal Weight rating on the shares after the company reported positive interim Phase…
Absci price target raised to $16 from $8 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Absci (ABSI) to $16 from $8 and keeps a Buy rating on the shares. The firm now includes ABS-201 endometriosis sales into…
Absci prices 13.5M shares at $7.41 in public offering
Absci (ABSI) announced the pricing of an underwritten offering of 13,495,277 shares of its common stock at a price of $7.41 per share, before deducting underwriting discounts and commissions. The…
Absci reports Phase 1 data from human trial of ABS-201
Absci (ABSI) reported positive interim Phase 1 data from its first-in-human trial of ABS-201, an investigational anti-prolactin receptor, or PRLR, antibody. The ABS-201 Phase 1 trial is an ongoing, fi...
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts